Outcome of Chimeric Antigen Receptor T Cell Therapy Following Treatment with Inotuzumab Ozogamicin in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia

The authors investigated whether prior use of inotuzumab ozogamicin , an anti-CD22 antibody conjugated to calicheamicin, may impact CAR T-cell manufacturing or efficacy via pre-CART-19 depletion of the B-cell compartment.